As many health care practices look to build precision medicine programs, access to clinical NGS testing for every patient is currently limited by several challenges.Here we will discuss several technical and biological challenges to library preparation and explore options for overcoming those shortcomings.
In this study, we compared the whole transcriptome from formalin-fixed paraffin-embedded specimens of primary tumors and subsequent passages of PDX models developed by DFCI investigators with a view to conducting future preclinical studies in vivo.
Analytical Validation of a Liquid Biopsy NGS Assay Lin Wu, Ph.
Our mission at the Stanford Genome Technology Center is to develop technologies that increase the speed, precision, and cost-effectiveness of genomic analyses and healthcare.
Many of our technologies are based on direct electrical detection of molecular and cellular phenomena.
LR sequencing allows for identification of a wider variety of variants, reconstruction of haplotypes, and access to repetitive sequences.
Disease-causing variation in samples with variants undetectable by standard SRs can be detected with LRs.
The test offers a rapid, comprehensive and cost-effective way to interrogate patient samples with achievement of sensitivities of 0.01%-0.1%.
Technologies for Biosensing and Precision Health Ronald W. D., Director of the Stanford Genome Technology Center, Professor of Biochemistry and of Genetics, Department of Biochemistry, Department of Genetics, Stanford School of Medicine Breakthroughs in biomedical research are driven by technological developments.
You spend 00’s in reagents and time testing a sample just to find out that it’s not going to work for your project.